Full Text of PDF (411k)
Article in Japanese
Abstract
Case Report
A case of small cell lung cancer that developed anti-recoverin antibody-positive retinopathy after administration of atezolizumab
Koji Kubotaa,b Keiko Mizunoa Shunsuke Yasudaa Takahiro Matsuyamaa Tetsuro Hamasakib Hiromasa Inouea
aDepartment of Pulmonary Medicine, Graduate School of Medical & Dental Sciences, Kagoshima University
bDepartment of Respiratory Medicine, Nanpuh Hospital
ABSTRACT
An 86-year-old man with extensive-stage small cell lung cancer received first-line chemotherapy with carboplatin, etoposide, and atezolizumab. After four courses of chemotherapy, the visual acuity in both his eyes decreased rapidly. Following a detailed examination, the patient was diagnosed with anti-recoverin antibody-positive retinopathy. Discontinuation of atezolizumab and initiation of steroid treatment alleviated the visual impairment. Retinopathy with an autoimmune mechanism rarely develops after the start of lung cancer treatment, and it is considered that immune checkpoint inhibitors may have been involved.
KEYWORDS
Atezolizumab Cancer-associated retinopathy (CAR) Autoimmune retinopathy Small cell lung cancer (SCLC) Immune-related adverse event (irAE)
Received 3 Mar 2022 ／ Accepted 20 Sep 2022
AJRS, 11(6): 345-349, 2022
Copyright © The Japanese Respiratory Society All Rights Reserved.